Intravenous infusion of NAD+ versus nicotinamide riboside: a retrospective tolerability pilot study in a real-world setting
Researchers retrospectively reviewed medical records from a commercial wellness clinic to compare tolerability and short-term safety between intravenous NAD+ and nicotinamide riboside (NR) infusions, each given as four consecutive daily doses with 30-day follow-up. The study found differences in infusion time and tolerability between the two, while exploratory metabolic outcomes were variable — the authors noted that both are increasingly offered in commercial and wellness settings despite limited published evaluation of their safety and effectiveness.
This is a summary. The reporting is Frontiers in Aging's, and the link below goes to the original article.